Continuous subcutaneous insulin infusion (CSII), also known as insulin pump therapy and multiple dose insulin (MDI) are the two main intensified insulin regimens that have been used to achieve strict glycaemic control in patients with diabetes mellitus, especially with type 1 diabetes (T1DM). Each mode of therapy has its own merits and demerits. CSII is a costly and complex therapeutic intervention, but on the other hand provides flexibility, improves patient’s quality of life, glycaemic control and decreases hypoglycaemic episodes in certain situations. This review will summarize current evidence on CSII vs MDI on various outcomes. This will help health professionals to select the most appropriate method of insulin administration for the given situation.DOI: http://dx.doi.org/10.4038/sjdem.v4i1.7249SriTest Lanka Journal of Diabetes, Endocrinology and Metabolism 2014; 4: 22-29
Full Text Finder